Actively Recruiting
Intra-Articular Dexmedetomidine: A Treatment for Chronic Knee Pain
Led by Tanta University · Updated on 2024-10-15
70
Participants Needed
1
Research Sites
23 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Chronic knee osteoarthritis (KOA) is a painful condition with limited treatment options. Non-pharmacological approaches often fall short, leading to decreased quality of life. Ozone therapy, a simple and affordable treatment, has shown promise for pain relief. Dexmedetomidine (DEX), a sedative and analgesic, has been used successfully as an adjuvant to anesthesia and local anesthetics. Given its potential for pain management, exploring DEX as a treatment for KOA could offer a new and promising approach.
CONDITIONS
Official Title
Intra-Articular Dexmedetomidine: A Treatment for Chronic Knee Pain
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients were not assigned for surgical intervention
- Patients were free of exclusion criteria
You will not qualify if you...
- Patients were assigned for surgical intervention
- Patients who had uncontrolled hypertension and/or diabetes mellitus
- Patients who had uncompensated cardiac, renal, or hepatic diseases
- Patients with coagulopathy, spinal deformity, allergy, or contraindication for the used drugs
- Patients who refused to sign the informed consent were excluded from the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tanta University
Tanta, El Gharbyia, Egypt, 13511
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here